Arbutus Biopharma Corp. (ABUS)
4.29
+0.10
(+2.39%)
USD |
NASDAQ |
Oct 15, 16:00
4.28
-0.01
(-0.23%)
After-Hours: 20:00
Arbutus Biopharma Research and Development Expense (Quarterly) : 2.898M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.898M |
| March 31, 2026 | 4.12M |
| December 31, 2025 | 5.006M |
| September 30, 2025 | 5.778M |
| June 30, 2025 | 5.498M |
| March 31, 2025 | 8.959M |
| December 31, 2024 | 8.81M |
| September 30, 2024 | 14.27M |
| June 30, 2024 | 15.55M |
| March 31, 2024 | 15.40M |
| December 31, 2023 | 17.56M |
| September 30, 2023 | 20.17M |
| June 30, 2023 | 17.69M |
| March 31, 2023 | 18.28M |
| December 31, 2022 | 22.95M |
| September 30, 2022 | 20.06M |
| June 30, 2022 | 22.94M |
| March 31, 2022 | 18.46M |
| December 31, 2021 | 20.44M |
| September 30, 2021 | 16.30M |
| June 30, 2021 | 15.40M |
| March 31, 2021 | 13.37M |
| December 31, 2020 | 14.54M |
| September 30, 2020 | 12.06M |
| June 30, 2020 | 10.46M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.42M |
| December 31, 2019 | 12.42M |
| September 30, 2019 | 17.73M |
| June 30, 2019 | 12.74M |
| March 31, 2019 | 14.71M |
| December 31, 2018 | 11.06M |
| September 30, 2018 | 16.57M |
| June 30, 2018 | 16.36M |
| March 31, 2018 | 13.95M |
| December 31, 2017 | 17.82M |
| September 30, 2017 | 15.54M |
| June 30, 2017 | 15.44M |
| March 31, 2017 | 13.87M |
| December 31, 2016 | 15.66M |
| September 30, 2016 | 14.24M |
| June 30, 2016 | 14.72M |
| March 31, 2016 | 11.94M |
| December 31, 2015 | 13.50M |
| September 30, 2015 | 14.85M |
| June 30, 2015 | 9.29M |
| March 31, 2015 | 9.657M |
| December 31, 2014 | 11.90M |
| September 30, 2014 | 9.309M |
| June 30, 2014 | 9.298M |
| March 31, 2014 | 8.204M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Insmed, Inc. | 210.03M |
| Pfizer Inc. | 2.746B |
| Gossamer Bio, Inc. | 26.41M |
| Legend Biotech Corp. | 96.16M |
| Moderna, Inc. | 588.00M |